On January 23, 2024, Legend Biotech reported that its applications seeking expanded use of CARVYKTI® for relapsed/refractory multiple myeloma are under review by U.S. and European health authorities, supported by Phase 3 CARTITUDE-4 study results. Additionally, the FDA has issued labeling updates for CAR-T therapies, including CARVYKTI®, following new safety information identified on November 28, 2023.